Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Histone demethylase that specifically demethylates 'Lys- 9' of histone H3, thereby playing a role in histone code. Additionally we are shipping and many more products for this protein.
Showing 10 out of 148 products:
Human Polyclonal KDM4B Primary Antibody for IP, WB - ABIN261682
Beyer, Kristensen, Jensen, Johansen, Staller: The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. in The Journal of biological chemistry 2008
Show all 3 Pubmed References
Human Polyclonal KDM4B Primary Antibody for EIA, WB - ABIN952974
Pollard, Loenarz, Mole, McDonough, Gleadle, Schofield, Ratcliffe: Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. in The Biochemical journal 2008
Show all 3 Pubmed References
Human Polyclonal KDM4B Primary Antibody for EIA, FACS - ABIN952973
Katoh, Katoh: Comparative integromics on JMJD2A, JMJD2B and JMJD2C: preferential expression of JMJD2C in undifferentiated ES cells. in International journal of molecular medicine 2007
Show all 5 Pubmed References
Chicken Polyclonal KDM4B Primary Antibody for ChIP, IP - ABIN261681
Uribe, Buzzi, Bronner, Strobl-Mazzulla: Histone demethylase KDM4B regulates otic vesicle invagination via epigenetic control of Dlx3 expression. in The Journal of cell biology 2015
KDM4B may play an important role in mitochondrial apoptosis and represent a potential therapeutic cancer target in colorectal cancer
High KDM4B expression is associated with Neuroblastomas.
This is the first demonstration that a Jumonji (show JARID2 Antibodies)-domain histone demethylase (show MBD2 Antibodies) regulates cellular processes required for peritoneal dissemination of cancer cells, one of the predominant factors affecting prognosis of EOC. The pathways regulated by KDM4B may present novel opportunities to develop combinatorial therapies to improve existing therapies for EOC patients.
identification of JMJD2B/KDM4B as a p53 (show TP53 Antibodies)-inducible gene in response to DNA damage.
KDM4B and KDM4D (show KDM4D Antibodies) expression may associate with an aggressive subtype of classical Hodgkin lymphoma and be linked with radioresistance
KDM4B is a key mediator in epithelial-mesenchymal transition process, and may serve as an important prognostic marker and therapeutic target for the metastatic progression of human pancreatic cancer
The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7% vs. 92.6%; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor. CONCLUSION: JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma
upon TGF-beta (show TGFB1 Antibodies) stimulation, KDM4B was recruited to the SOX9 (show SOX9 Antibodies) promoter, removed the silencing H3K9me3 marks, and activated the transcription of SOX9 (show SOX9 Antibodies).
High KDM4B expression is associated with endometrial cancer progression.
JMJD2B and JMJD2C (show KDM4C Antibodies) play an important role in the pathology of osteosarcoma via the up-regulation of FGF2 (show FGF2 Antibodies).
results indicate that JMJD2B regulates PPARgamma (show PPARG Antibodies) and C/EBPalpha (show CEBPA Antibodies) during adipogenesis
JMJD2B-deficient mice exhibited hyperactive behavior, sustained hyperactivity in a novel environment, deficits in working memory and spontaneous epileptic-like seizures.
KDM4B histone demethylase (show MBD2 Antibodies) regulates expression of myogenic regulators such as MyoD (show MYOD1 Antibodies) and thereby controls myogenic differentiation of C2C12 myoblast cells.
Jmjd2b unique, Jmjd2c (show KDM4C Antibodies) unique, and Jmjd2b-Jmjd2c (show KDM4C Antibodies) common target sites belong to functionally separable Core, Polycomb (show CBX2 Antibodies) repressive complex (PRC (show PPRC1 Antibodies)), and Myc (show MYC Antibodies) regulatory modules, respectively.
This study establishes novel Jmjd2b targets that potentiate a biological rationale involving Jmjd2b in NSC inflammation.
The promoter of Kdm4b is bound and activated by C/EBPbeta (show CEBPB Antibodies)
Induction of Jmjd2b in the embryonic stem cells decreased total levels of histone-3 lysine-9 trimethylation (H3K9me3) by 63%.
Data indicate that Myst4 (show KAT6B Antibodies), Jmjd2b, Aof1 (show KDM1B Antibodies) genes are regulated by H3K9me under hyperinsulinemia/hyperglycemia.
A subgroup of murine Jmjd2 (show KDM4A Antibodies) proteins antagonize H3K9me3 at pericentric heterochromatin.
Histone demethylase that specifically demethylates 'Lys- 9' of histone H3, thereby playing a role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27', H3 'Lys-36' nor H4 'Lys-20'. Only able to demethylate trimethylated H3 'Lys-9', with a weaker activity than KDM4A, KDM4C and KDM4D. Demethylation of Lys residue generates formaldehyde and succinate.
lysine (K)-specific demethylase 4B
, jumonji domain containing 2B
, lysine-specific demethylase 4B
, lysine-specific demethylase 4B-like
, jmjC domain-containing histone demethylation protein 3B
, jumonji domain-containing protein 2B
, tudor domain containing 14B